LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, article, google, scholar, pubmed, cas, cantuzumab, mertansine, phase, study, threetimes, schedule, canag, immunoconjugate, maytansine, usa, privacy, cookies, pharmacokinetic, tolcher, antibody, antigen, treatment, weekly, res, content, information, publish, research, search, chemotherapy, week, rodon, hammond, smith, lambert, maytansinoid, drug, doses, patients, expression, mgm, immunoconjugates, access, therapy, clin, treat, author, data, log,

Topics {✒️}

month download article/chapter antibody-drug conjugates designed full-length antibody molecules linker-dependent intracellular processing maytansinoid drug dm1 article cancer chemotherapy cytotoxic drug immunoconjugates privacy choices/manage cookies full article pdf huc242–dm1 antibody–maytansinoid conjugates cantuzumab mertansine iv sb-408075 investigator brochure cantuzumab mertansine administered documented canag expression targets canag antigen european economic area johann de bono maximum tolerated dose dose-limiting toxicity neurosensory effects occurred determine pharmacokinetic parameters antibody huc242 conditions privacy policy advanced solid tumors transaminitis precluded tolerance higher dose density malignant pancreatic lesions single intravenous infusion research center cancer therapy targeted cancer cells dose-intense treatment accepting optional cookies biologic correlative study maytansinoid immunoconjugate directed tolcher aw cancer chemotherapy article rodon plasma cea trends chris takimoto & anthony journal finder publish antitumor agent maytansine maria howard cantuzumab mertansine kovtun yv 4-week schedule proved article log martino hk jordi rodon

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
         description:Cantuzumab mertansine (SB-408075; huC242–DM1) is a conjugate of the maytansinoid drug DM1 to the antibody huC242, which targets CanAg antigen. In previous studies, cantuzumab mertansine was considered safe and tolerable, but transaminitis precluded tolerance of higher doses. Based on those studies, it was suggested that treatment at intervals of the half-life of the intact immunoconjugate may allow a higher dose density. This provided the rationale for the three-times weekly treatment explored in this protocol. Patients with advanced solid tumors and documented CanAg expression were treated with escalating doses of cantuzumab mertansine IV administered three-times a week in a 3 out of 4 weeks schedule. Plasma samples were assayed to determine pharmacokinetic parameters. Twenty patients (pts) with colon (11/20), rectal carcinomas (2/20), or other malignancies (7/20) were treated with doses ranging from 30 to 60 mg/m2 per day of cantuzumab mertansine IV three-times a week. The maximum tolerated dose (MTD) was 45 mg/m2, and the dose-limiting toxicity was grade 3 transaminitis. Hepatic, hematologic, and neurosensory effects occurred, but were rarely severe with repetitive treatment at doses of 45 mg/m2. Treatment with cantuzumab mertansine at 45 mg/m2 per day three-times weekly × 3-every-4-week schedule proved that a dose-intense treatment with an immunoconjugate can be safely administered. The pharmacokinetic profile of the intact immunoconjugate indicates that the linker is cleaved with a half-life of about 2 days, resulting in faster clearance of the maytansinoid relative to the antibody. Therefore, with the development of second-generation immunoconjugates, there is a need for improvement of the immunoconjugate linker to take full advantage of the slow clearance of full-length antibody molecules.
         datePublished:2008-02-27T00:00:00Z
         dateModified:2008-02-27T00:00:00Z
         pageStart:911
         pageEnd:919
         sameAs:https://doi.org/10.1007/s00280-007-0672-8
         keywords:
            Cantuzumab mertansine
            SB-408075
            huC242–DM1
            CanAg
            Immunoconjugates
            Pharmacokinetics
            Phase I
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-007-0672-8/MediaObjects/280_2007_672_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-007-0672-8/MediaObjects/280_2007_672_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-007-0672-8/MediaObjects/280_2007_672_Fig3_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:62
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jordi Rodon
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mitchell Garrison
               affiliation:
                     name:Brooke Army Medical Center
                     address:
                        name:Brooke Army Medical Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lisa A. Hammond
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Johann de Bono
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lon Smith
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Leonardo Forero
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Desirée Hao
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chris Takimoto
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John M. Lambert
               affiliation:
                     name:ImmunoGen
                     address:
                        name:ImmunoGen, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lini Pandite
               affiliation:
                     name:Glaxo SmithKline
                     address:
                        name:Glaxo SmithKline, Collegeville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria Howard
               affiliation:
                     name:ImmunoGen
                     address:
                        name:ImmunoGen, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hongsheng Xie
               affiliation:
                     name:ImmunoGen
                     address:
                        name:ImmunoGen, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anthony W. Tolcher
               affiliation:
                     name:Institute for Drug Development, Cancer Therapy and Research Center
                     address:
                        name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
      description:Cantuzumab mertansine (SB-408075; huC242–DM1) is a conjugate of the maytansinoid drug DM1 to the antibody huC242, which targets CanAg antigen. In previous studies, cantuzumab mertansine was considered safe and tolerable, but transaminitis precluded tolerance of higher doses. Based on those studies, it was suggested that treatment at intervals of the half-life of the intact immunoconjugate may allow a higher dose density. This provided the rationale for the three-times weekly treatment explored in this protocol. Patients with advanced solid tumors and documented CanAg expression were treated with escalating doses of cantuzumab mertansine IV administered three-times a week in a 3 out of 4 weeks schedule. Plasma samples were assayed to determine pharmacokinetic parameters. Twenty patients (pts) with colon (11/20), rectal carcinomas (2/20), or other malignancies (7/20) were treated with doses ranging from 30 to 60 mg/m2 per day of cantuzumab mertansine IV three-times a week. The maximum tolerated dose (MTD) was 45 mg/m2, and the dose-limiting toxicity was grade 3 transaminitis. Hepatic, hematologic, and neurosensory effects occurred, but were rarely severe with repetitive treatment at doses of 45 mg/m2. Treatment with cantuzumab mertansine at 45 mg/m2 per day three-times weekly × 3-every-4-week schedule proved that a dose-intense treatment with an immunoconjugate can be safely administered. The pharmacokinetic profile of the intact immunoconjugate indicates that the linker is cleaved with a half-life of about 2 days, resulting in faster clearance of the maytansinoid relative to the antibody. Therefore, with the development of second-generation immunoconjugates, there is a need for improvement of the immunoconjugate linker to take full advantage of the slow clearance of full-length antibody molecules.
      datePublished:2008-02-27T00:00:00Z
      dateModified:2008-02-27T00:00:00Z
      pageStart:911
      pageEnd:919
      sameAs:https://doi.org/10.1007/s00280-007-0672-8
      keywords:
         Cantuzumab mertansine
         SB-408075
         huC242–DM1
         CanAg
         Immunoconjugates
         Pharmacokinetics
         Phase I
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-007-0672-8/MediaObjects/280_2007_672_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-007-0672-8/MediaObjects/280_2007_672_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-007-0672-8/MediaObjects/280_2007_672_Fig3_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:62
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jordi Rodon
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mitchell Garrison
            affiliation:
                  name:Brooke Army Medical Center
                  address:
                     name:Brooke Army Medical Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lisa A. Hammond
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Johann de Bono
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lon Smith
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Leonardo Forero
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Desirée Hao
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chris Takimoto
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John M. Lambert
            affiliation:
                  name:ImmunoGen
                  address:
                     name:ImmunoGen, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lini Pandite
            affiliation:
                  name:Glaxo SmithKline
                  address:
                     name:Glaxo SmithKline, Collegeville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria Howard
            affiliation:
                  name:ImmunoGen
                  address:
                     name:ImmunoGen, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hongsheng Xie
            affiliation:
                  name:ImmunoGen
                  address:
                     name:ImmunoGen, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anthony W. Tolcher
            affiliation:
                  name:Institute for Drug Development, Cancer Therapy and Research Center
                  address:
                     name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:62
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:Brooke Army Medical Center
      address:
         name:Brooke Army Medical Center, San Antonio, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
      name:ImmunoGen
      address:
         name:ImmunoGen, Cambridge, USA
         type:PostalAddress
      name:Glaxo SmithKline
      address:
         name:Glaxo SmithKline, Collegeville, USA
         type:PostalAddress
      name:ImmunoGen
      address:
         name:ImmunoGen, Cambridge, USA
         type:PostalAddress
      name:ImmunoGen
      address:
         name:ImmunoGen, Cambridge, USA
         type:PostalAddress
      name:Institute for Drug Development, Cancer Therapy and Research Center
      address:
         name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jordi Rodon
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mitchell Garrison
      affiliation:
            name:Brooke Army Medical Center
            address:
               name:Brooke Army Medical Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Lisa A. Hammond
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Johann de Bono
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Lon Smith
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Leonardo Forero
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Desirée Hao
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Chris Takimoto
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:John M. Lambert
      affiliation:
            name:ImmunoGen
            address:
               name:ImmunoGen, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Lini Pandite
      affiliation:
            name:Glaxo SmithKline
            address:
               name:Glaxo SmithKline, Collegeville, USA
               type:PostalAddress
            type:Organization
      name:Maria Howard
      affiliation:
            name:ImmunoGen
            address:
               name:ImmunoGen, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Hongsheng Xie
      affiliation:
            name:ImmunoGen
            address:
               name:ImmunoGen, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Anthony W. Tolcher
      affiliation:
            name:Institute for Drug Development, Cancer Therapy and Research Center
            address:
               name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:Brooke Army Medical Center, San Antonio, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
      name:ImmunoGen, Cambridge, USA
      name:Glaxo SmithKline, Collegeville, USA
      name:ImmunoGen, Cambridge, USA
      name:ImmunoGen, Cambridge, USA
      name:Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(92)

• What's the financial outcome of https://www.springernature.com/gp/authors?
• What is the earnings of https://link.springernature.com/home/?
• How much income is https://order.springer.com/public/cart earning monthly?
• Check the income stats for https://submission.springernature.com/new-submission/280/3
• How much income does https://www.springernature.com/gp/librarians/licensing/agc/journals have?
• What's https://doi.org/10.1038%2Fncponc0774's gross income?
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17392715?
• How much does http://scholar.google.com/scholar_lookup?&title=Technology%20insight%3A%20cytotoxic%20drug%20immunoconjugates%20for%20cancer%20therapy&journal=Nat%20Clin%20Pract%20Oncol&doi=10.1038%2Fncponc0774&volume=4&issue=4&pages=245-255&publication_year=2007&author=Ricart%2CAD&author=Tolcher%2CAW earn?
• What's the financial gain of https://doi.org/10.1038%2Fnbt1141?
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16151407's earnings
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Arming%20antibodies%3A%20prospects%20and%20challenges%20for%20immunoconjugates&journal=Nat%20Biotechnol&doi=10.1038%2Fnbt1141&volume=23&issue=9&pages=1137-1146&publication_year=2005&author=Wu%2CAM&author=Senter%2CPD?
• Check the income stats for https://doi.org/10.1006%2Fbbrc.2001.4775
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11341784's revenue stream
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Identification%20of%20MUC1%20proteolytic%20cleavage%20sites%20in%20vivo&journal=Biochem%20Biophys%20Res%20Commun&doi=10.1006%2Fbbrc.2001.4775&volume=283&issue=3&pages=715-720&publication_year=2001&author=Parry%2CS&author=Silverman%2CHS&author=McDermott%2CK&author=Willis%2CA&author=Hollingsworth%2CMA&author=Harris%2CA generate?
• Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8080735
• How much does http://scholar.google.com/scholar_lookup?&title=CA%20242%2C%20a%20new%20tumour%20marker%20for%20pancreatic%20cancer%3A%20a%20comparison%20with%20CA%2019-9%2C%20CA%2050%20and%20CEA&journal=Br%20J%20Cancer&volume=70&issue=3&pages=487-492&publication_year=1994&author=Haglund%2CC&author=Lundin%2CJ&author=Kuusela%2CP&author=Roberts%2CPJ bring in each month?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2557879 net monthly?
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Tissue%20expression%20of%20the%20tumour%20associated%20antigen%20CA242%20in%20benign%20and%20malignant%20pancreatic%20lesions.%20A%20comparison%20with%20CA%2050%20and%20CA%2019-9&journal=Br%20J%20Cancer&volume=60&issue=6&pages=845-851&publication_year=1989&author=Haglund%2CC&author=Lindgren%2CJ&author=Roberts%2CPJ&author=Kuusela%2CP&author=Nordling%2CS?
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=455300?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Cell%20cycle%20phase-specific%20cytotoxicity%20of%20the%20antitumor%20agent%20maytansine&journal=Cancer%20Res&volume=39&issue=8&pages=3152-3155&publication_year=1979&author=Rao%2CPN&author=Freireich%2CEJ&author=Smith%2CML&author=Loo%2CTL
• How much does https://doi.org/10.1016%2FS0305-7372%2878%2980014-0 net monthly?
• Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=367597
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Maytansine&journal=Cancer%20Treat%20Rev&doi=10.1016%2FS0305-7372%2878%2980014-0&volume=5&issue=4&pages=199-207&publication_year=1978&author=Issell%2CBF&author=Crooke%2CST generate?
• Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15663331
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=Technology%20evaluation%3A%20cantuzumab%20mertansine%2C%20ImmunoGen&journal=Curr%20Opin%20Mol%20Ther&volume=6&issue=6&pages=666-674&publication_year=2004&author=Smith%2CSV each month?
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=SB-408075%20investigator%20brochure&publication_year=2000&author=Lambert%2CJ&author=DeWitte%2CM&author=Martino%2CHK each month?
• How much income does https://doi.org/10.1158%2F0008-5472.CAN-05-3973 have?
• How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16540673?
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Antibody-drug%20conjugates%20designed%20to%20eradicate%20tumors%20with%20homogeneous%20and%20heterogeneous%20expression%20of%20the%20target%20antigen&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-05-3973&volume=66&issue=6&pages=3214-3221&publication_year=2006&author=Kovtun%2CYV&author=Audette%2CCA&author=Ye%2CY&author=Xie%2CH&author=Ruberti%2CMF&author=Phinney%2CSJ?
• What's the financial gain of https://doi.org/10.1200%2FJCO.2003.05.137?
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12525512 makes per month
• Get to know http://scholar.google.com/scholar_lookup?&title=Cantuzumab%20mertansine%2C%20a%20maytansinoid%20immunoconjugate%20directed%20to%20the%20CanAg%20antigen%3A%20a%20phase%20I%2C%20pharmacokinetic%2C%20and%20biologic%20correlative%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2003.05.137&volume=21&issue=2&pages=211-222&publication_year=2003&author=Tolcher%2CAW&author=Ochoa%2CL&author=Hammond%2CLA&author=Patnaik%2CA&author=Edwards%2CT&author=Takimoto%2CC's earnings
• Get to know https://doi.org/10.1158%2F1078-0432.CCR-04-0088's earnings
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15240523
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=A%20phase%20I%20study%20of%20cantuzumab%20mertansine%20administered%20as%20a%20single%20intravenous%20infusion%20once%20weekly%20in%20patients%20with%20advanced%20solid%20tumors&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-04-0088&volume=10&issue=13&pages=4363-4368&publication_year=2004&author=Helft%2CPR&author=Schilsky%2CRL&author=Hoke%2CFJ&author=Williams%2CD&author=Kindler%2CHL&author=Sprague%2CE?
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=348312's gross income?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Maytansine%3A%20a%20phase%20I%20study%20of%20an%20ansa%20macrolide%20with%20antitumor%20activity&journal=Cancer%20Treat%20Rep&volume=62&issue=3&pages=435-438&publication_year=1978&author=Blum%2CRH&author=Kahlert%2CT
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=348310 generate?
• How much income does http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20maytansine%20using%20a%203-day%20schedule&journal=Cancer%20Treat%20Rep&volume=62&issue=3&pages=425-428&publication_year=1978&author=Cabanillas%2CF&author=Rodriguez%2CV&author=Hall%2CSW&author=Burgess%2CMA&author=Bodey%2CGP&author=Freireich%2CEJ have?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=526928
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20weekly%20maytansine%20given%20by%20iv%20bolus%20or%2024-hour%20infusion&journal=Cancer%20Treat%20Rep&volume=63&issue=11%E2%80%9312&pages=1953-1960&publication_year=1979&author=Chahinian%2CAP&author=Nogeire%2CC&author=Ohnuma%2CT&author=Greenberg%2CML&author=Sivak%2CM&author=Jaffrey%2CIS is on a monthly basis
• What's the monthly income of https://doi.org/10.1002%2F1097-0142%2819800901%2946%3A5%3C1104%3A%3AAID-CNCR2820460505%3E3.0.CO%3B2-T?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7214295 produce monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=A%20phase%20I%E2%80%93II%20study%20of%20maytansine%20utilizing%20a%20weekly%20schedule&journal=Cancer&doi=10.1002%2F1097-0142%2819800901%2946%3A5%3C1104%3A%3AAID-CNCR2820460505%3E3.0.CO%3B2-T&volume=46&issue=5&pages=1104-1108&publication_year=1980&author=Franklin%2CR&author=Samson%2CMK&author=Fraile%2CRJ&author=Abu-Zahra%2CH&author=O%E2%80%99Bryan%2CR&author=Baker%2CLH bring in each month?
• See how much https://doi.org/10.1158%2F0008-5472.CAN-05-4489 makes per month
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16618769 pull in?
• Profit of http://scholar.google.com/scholar_lookup?&title=Antibody%E2%80%93maytansinoid%20conjugates%20are%20activated%20in%20targeted%20cancer%20cells%20by%20lysosomal%20degradation%20and%20linker-dependent%20intracellular%20processing&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-05-4489&volume=66&issue=8&pages=4426-4433&publication_year=2006&author=Erickson%2CHK&author=Park%2CPU&author=Widdison%2CWC&author=Kovtun%2CYV&author=Garrett%2CLM&author=Hoffman%2CK
• What's the financial intake of https://citation-needed.springer.com/v2/references/10.1007/s00280-007-0672-8?format=refman&flavour=references?
• Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jordi%20Rodon
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jordi%20Rodon%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
• What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mitchell%20Garrison?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mitchell%20Garrison%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lisa%20A.%20Hammond earn?
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lisa%20A.%20Hammond%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Johann%20de%20Bono
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Johann%20de%20Bono%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lon%20Smith make?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lon%20Smith%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en income
• What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Leonardo%20Forero?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Leonardo%20Forero%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Desir%C3%A9e%20Hao generate?
• What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Desir%C3%A9e%20Hao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chris%20Takimoto
• What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chris%20Takimoto%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=John%20M.%20Lambert generate?
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22John%20M.%20Lambert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lini%20Pandite make?
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lini%20Pandite%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Maria%20Howard earns monthly
• Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Maria%20Howard%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hongsheng%20Xie pull in?
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hongsheng%20Xie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Anthony%20W.%20Tolcher earns monthly
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Anthony%20W.%20Tolcher%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://s100.copyright.com/AppDispatchServlet?title=Cantuzumab%20mertansine%20in%20a%20three-times%20a%20week%20schedule%3A%20a%20phase%20I%20and%20pharmacokinetic%20study&author=Jordi%20Rodon%20et%20al&contentID=10.1007%2Fs00280-007-0672-8©right=Springer-Verlag&publication=0344-5704&publicationDate=2008-02-27&publisherName=SpringerNature&orderBeanReset=true make?
• Discover the revenue of https://citation-needed.springer.com/v2/references/10.1007/s00280-007-0672-8?format=refman&flavour=citation
• How much cash flow does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral have monthly?
• Profit of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• Learn how profitable https://www.springernature.com/gp/products is on a monthly basis
• How much revenue does https://www.springernature.com/gp/librarians produce monthly?
• Financial intake of https://www.springernature.com/gp/societies
• Get to know https://www.springernature.com/gp/partners's earnings
• Get to know what's the income of https://www.springer.com/
• Get to know what's the income of https://www.nature.com/
• How much does https://www.biomedcentral.com/ gross monthly?
• How much does https://www.palgrave.com/ generate monthly?
• What are the total earnings of https://www.apress.com/?
• How much income is https://www.springernature.com/gp/legal/ccpa earning monthly?
• How much revenue does https://www.springernature.com/gp/info/accessibility bring in?
• How much revenue does https://support.springernature.com/en/support/home bring in?
• How much income does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations have?
• See how much https://www.springernature.com/ makes per month

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref